These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm. Wanebo JE; Arthur AS; Louis HG; West K; Kassell NF; Lee KS; Helm GA Neurosurgery; 1998 Dec; 43(6):1409-17; discussion 1417-8. PubMed ID: 9848855 [TBL] [Abstract][Full Text] [Related]
9. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. Waxman AB Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185 [TBL] [Abstract][Full Text] [Related]
10. Sitaxsentan for treatment of pulmonary hypertension. Wittbrodt ET; Abubakar A Ann Pharmacother; 2007 Jan; 41(1):100-5. PubMed ID: 17164394 [TBL] [Abstract][Full Text] [Related]
16. Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. O'Callaghan DS; Gaine SP Int J Clin Pract; 2006 Apr; 60(4):475-81. PubMed ID: 16620363 [TBL] [Abstract][Full Text] [Related]
17. Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Humbert M; Simonneau G Nat Clin Pract Rheumatol; 2005 Dec; 1(2):93-101. PubMed ID: 16932638 [TBL] [Abstract][Full Text] [Related]
18. Will endothelin receptor antagonists have a role in heart failure? Spieker LE; Lüscher TF Med Clin North Am; 2003 Mar; 87(2):459-74. PubMed ID: 12693734 [TBL] [Abstract][Full Text] [Related]
19. Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. Horn EM; Widlitz AC; Barst RJ Expert Opin Investig Drugs; 2004 Nov; 13(11):1483-92. PubMed ID: 15500395 [TBL] [Abstract][Full Text] [Related]